全球流感疫苗市場:市場機會·課題·市場預測 是由出版商Renub Research在2012年01月所出版的。
這份英文市場調查報告書包含80 Pages 價格從美金1100起跳。
疫苗市場過去很難進入，推翻了業界的普遍看法的利潤減少，過去數年之間再次產生高度關注。特別是流感疫苗市場由於對不久的將來的大流行的恐懼等，成為關注的對象。因此，全球流感疫苗市場在2008年到2010年達到65％以上的年平均成長率，有驚人的成長。
本報告提供全球流感疫苗市場現況與展望調查分析，市場規模的轉變與預測(∼2015年)，地區/國家·流感類型·主要疫苗品牌各類型詳細內容，市場成長的各種推進因素分析，主要經營者的收益·企業分析等彙整，為您概述為以下內容。
第1章 摘要整理
第2章 全球流感疫苗市場和其預測
- 全球季節性流感疫苗市場和其預測
- 全球豬流感(H1N1)疫苗市場和其預測
- 全球大流行性流感(1918-2009年)
- 各國豬流感疫苗施打指示(2009年)
- 流感疫苗市場上收購與合併
第3章 季節性流感疫苗市場地區的分佈(2005-2010年2015年)
第4章 全球季節性流感疫苗品牌的市場與預測開發平台分析
- Fluarix & Flulaval:銷售額實際成果與預測
- Afluria:銷售額實際成果與預測
- FluMist:銷售額實際成果與預測
- Influvac:銷售額實際成果與預測
第5章 豬流感疫苗市場分析:競爭環境
- AstraZeneca:銷售額實際成果
- GlaxoSmithKline:銷售額實際成果
- Novartis:銷售額實際成果
- Sanofi-Pasteur:銷售額實際成果
第6章 流感疫苗市場成長推進因素
- 流感的患病率的增加
- 新的疫苗技術
- 有效的傳播策略
- 疫苗接種的合法性
- 疫苗:最具成本效益的疾病預防
第7章 流感疫苗市場相關課題
- 認證疫苗利用的障礙和最好的利用法
- 流感疫苗的開發及認證制度的電子處方的複雜性與產品開發的威脅
- 法律上的障礙
- 一般技術上障礙
- 經濟障礙
- 法規上的障礙
- 疫苗開發的計劃的縮短
第8章 企業分析
- GlaxoSmithKline
- AstraZeneca
- Novartis AG
- Sanofi Pasteur
Abstract
Influenza Vaccine Market Overview
Last few years have seen renewed interest in the vaccines market, overcoming
the prevailing view that vaccines are a low-margin business with high barriers
to entry. The flu vaccines market has been at the forefront of this trend,
partially fuelled by the fear of an impending pandemic. As a result global
influenza vaccine market has experienced phenomenal growth in recent years at
a compound annual growth rate of more than 65% between 2008 and 2010. This
growth was mainly driven by the global spread of H1N1 influenza. But in the
year 2011 H1N1 pandemic flu vaccine market declined due to waning threat of
swine flu disease. However seasonal influenza vaccine market is predicted to
grow year on year and cross US$ 4 Billion by 2015.
From our research findings Unites States is the largest market for influenza
vaccine market in 2010. In seasonal influenza vaccine brands like Fluarix &
Flulaval had highest sales for 2010. Unlike some other pharmaceutical
products, influenza vaccines are equally important in both developed and
developing nations. In the developing countries, dealing with infectious
diseases remains the highest priority in healthcare. It is predicted that in
the next 5-6 years seasonal influenza vaccine sales would increase
significantly.
Renub Research report entitled " Influenza Vaccine Market Opportunities and
Challenges: Worldwide Forecast" critically examines the influenza vaccines
market through a comprehensive review of information. This report provides
market prospects, Key products detailed sales forecasts, discussions of
pipeline developments and analyses of commercial drivers and challenges,
including revenue of key players from seasonal and H1N1 influenza vaccine as
well as Strengths and Weakness analysis of key players in influenza vaccine
segment.
This report examines the following markets for influenza vaccines:
- Global Influenza vaccine market (2005 - 2015)
- Global Seasonal influenza vaccine market has been covered from (2003 -
2015)
- Global Swine Flu (H1N1) influenza vaccine market has been covered from
(2009 - 2012)
- Top 7 Countries (United States, Germany, France, Italy, Spain, United
Kingdom, Japan) seasonal vaccine market data from (2005 - 2015)
- Top Brands Seasonal influenza vaccine market performance (Fluarix,
Afluria, Flumist, Influvac) market performance and forecast
- Top companies Swine Flu vaccine market performance (AstraZeneca,
GlaxoSmithKline, Novartis, Sanofi-Pasteur)
Companies Analysis
This section covers the key facts about the major companies that play an
important role in Influenza Vaccine Market. The companies analyzed in this
section are - GlaxoSmithKline, AstraZeneca, Novartis AG and Sanofi Pasteur.
All the companies have been analyzed from three headings
- 1) Revenue of the company from influenza vaccines (swine flu & seasonal
flu)
- 2) Strength of the company in influenza vaccine market
- 3) Weakness of the company in influenza vaccine market
Data Sources
This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by Renub
Research team of industry experts.
Information and data has been collected from various printable and
non-printable sources like search engines, News websites, Government Websites,
Trade Journals, White papers, Government Agencies, Magazines, Newspapers,
Trade associations, Books, Industry Portals, Industry Associations and access
to more than 100 paid databases.
Table of Contents
1. Executive Summary
2. Worldwide Influenza Vaccine & Future Market
- 2.1 Worldwide Seasonal Influenza Vaccine & Future Market
- 2.2 Global Swine Flu (H1N1) Influenza Vaccine & Future Market
- 2.2.1 Global Pandemic Influenza Occur (1918 - 2009)
- 2.2.2 Country wise Swine Flu Vaccine Dose Order (2009)
- 2.3 Merger and Acquisition in Influenza Vaccine Market
3. Geographical Distribution - Seasonal Influenza Vaccine Market (2005 to 2015)
- 3.1 United States Seasonal Influenza Vaccine Market
- 3.2 Germany Seasonal Influenza Vaccine Market
- 3.3 France Seasonal Influenza Vaccine Market
- 3.4 Italy Seasonal Influenza Vaccine Market
- 3.5 Spain Seasonal Influenza Vaccine Market
- 3.6 United Kingdom Seasonal Influenza Vaccine Market
- 3.7 Japan Seasonal Influenza Vaccine Market
4. Worldwide - Seasonal Influenza Vaccine Brand Market & Forecast Pipeline Analysis
- 4.1 Fluarix & Flulaval - Sales Performance & Forecast
- 4.2 Afluria - Past, Present and Future Sales Performance
- 4.3 FluMist - Past, Present & Future Sales Performance
- 4.4 Influvac - Sales Performance & Future Forecast
5. Swine Flu Vaccine Market Analysis - Competitive Landscape
- 5.1 AstraZeneca Swine Flu Vaccine Sales Performance
- 5.2 GlaxoSmithKline Swine Flu Vaccine Sales Performance
- 5.3 Novartis Swine Flu Vaccines Sales Performance
- 5.4 Sanofi-Pasteur Swine Flu Vaccine Sales Performance
6. Growth Drivers in the Influenza Vaccines Market
- 6.1 Growing Prevalence of Influenza
- 6.2 Emerging Vaccine Technologies
- 6.3 Effective Communication Strategies
- 6.4 Compliance with Vaccination
- 6.5 Vaccines most Cost Effective Means of Disease Prevention
7. Challenges for Influenza Vaccine Market
- 7.1 Barriers to Optimal use of Licensed Vaccines
- 7.1.1 Technical Obstacles
- 7.1.2 Economic Obstacles
- 7.1.3 Cultural Obstacles
- 7.2 Complexity of Influenza Vaccine Development & Approval System Thwarts
Product Development
- 7.2.1 Legal Obstacles
- 7.2.2 General Technical Barriers
- 7.2.3 Economic Barriers
- 7.2.4 Regulatory Barriers
- 7.3 Shortening the Timeline for Vaccine Development
8. Company Analysis
- 8.1 GlaxoSmithKline
- 8.1.1 GSK Influenza Vaccine Revenue
- 8.1.2 GSK Influenza Vaccine Strengths
- 8.1.3 GSK Influenza Vaccine Weakness
- 8.2 AstraZeneca
- 8.2.1 AstraZeneca Influenza Vaccine Revenue
- 8.2.2 AstraZeneca Influenza Vaccine Strengths
- 8.2.3 Astrazeneca Influenza Vaccine Weakness
- 8.3 Novartis AG
- 8.3.1 Novartis AG Influenza Vaccine Strengths
- 8.3.2 Novartis AG Influenza Vaccine Weakness
- 8.4 Sanofi Pasteur
- 8.4.1 Sanofi-Pasteur Influenza Vaccine Revenue
- 8.4.2 Sanofi-Pasteur Influenza Vaccine Strengths
- 8.4.3 Sanofi-Pasteur Influenza Vaccine Weakness
